Corporate symposia
| Satellite symposium 1 Sponsored by Chongkundang |
17:30~18:00 / Thursday 10 October Emerald hall A Chairman:Sung Koo Kang |
|
|---|---|---|
|
SS1 Which is the better choice to diabetic patients with metabolic syndrom: TZD vs DPP-4 inhibitor | |
| Satellite symposium 2Sponsored by Sanofi Aventis |
17:30~18:00 / Thursday 10 October Emerald hall B Chairman:Ho-Young Son |
|
|---|---|---|
|
SS2 Safety and efficacy of glargine U300 in patients at high risk for hypoglycemia: results of data from randomized clinical trials and real world evidence | |
| Satellite symposium 3Sponsored by Handok |
15:20~16:00 / Friday 11 October Convention hall A Chairman:Kyungwan Min |
|
|---|---|---|
|
SS3 Real world data of switching between DPP-4 inhibitors in Korea | |
| Satellite symposium 4Sponsored by JW Pharmaceutical |
15:20~16:00 / Friday 11 October Convention hall B Chairman:Dong Seop Choi |
|
|---|---|---|
|
SS4 REAL-CAD trial, the largest randomized trial first performed in ASIA with pitavastatin | |
| Satellite symposium 5Sponsored by Astrazeneca |
15:20~16:00 / Friday 11 October Convention hall C Chairman:Yoo Lee Kim |
|
|---|---|---|
|
SS5 SGLT2 inhibitors in type 2 diabetes and cardio-renal diseases: dawn of a new Era? | |
| Breakfast symposium 1Sponsored by Novartis |
08:00~09:00 / Friday 11 October Grand Ballroom A Chairman:Min Young Chung |
|
|---|---|---|
|
BS1 How do you manage elderly T2DM patients? - safe and individualized treatment with vildagliptin | |
| Breakfast symposium 2Sponsored by Lilly |
08:00~09:00 / Friday 11 October Grand Ballroom C Chairman:Jae Myung Yu |
|
|---|---|---|
|
BS2 New treatment option for T2DM with once weekly GLP1-RA | |
| Breakfast symposium 3Sponsored by Sanofi Dong-A ST |
08:00~09:00 / Saturday 12 October Grand Ballroom A Chairman:You Hern Ahn |
|
|---|---|---|
|
BS3 Advanced clinical outcomes on 24hr glucose control-based on evergreen | |
| Breakfast symposium 4Sponsored by Boehringer Ingelheim |
08:00~09:00 / Saturday 12 October Grand Ballroom C Chairman:Hyung Joon Yoo |
|
|---|---|---|
|
BS4 Empagliflozin: broadening perspectives on CV outcomes, EMPA-REG OUTCOME and recent evidence | |
| Luncheon symposium 1Sponsored by Daewoong |
12:10~13:20 / Friday 11 October Convention hall A Chairman:Kyung Ah Han |
|
|---|---|---|
|
LS1 The renoprotective effect and safety of DPP-4 inhibitors for type 2 diabetes | |
| Luncheon symposium 2Sponsored by Novonordisk |
12:10~13:20 / Friday 11 October Convention hall B Chairman:Young Kil Choi |
|
|---|---|---|
|
LS2 Insulin degludeg and the alternative intensification with IDegLira | |
| Luncheon symposium 3Sponsored by MSD |
12:10~13:20 / Friday 11 October Convention hall C Chairman:Sung Woo Park |
|
|---|---|---|
|
LS3 Effect of race on glycemic effect of DPP4-I-TECOS | |
| Luncheon symposium 4Sponsored by Ildong |
12:10~13:20 / Friday 11 October Emerald hall A Chairman:Jin Woo Kim |
|
|---|---|---|
|
LS4 Efficacy and safety of DPP4 inhibitor in type 2 DM patients in the SAVOR & SPECIFY trials | |
| Luncheon symposium 5Sponsored by LG |
12:20~13:30 / Saturday 12 October Convention hall A Chairman:Moon-Suk Nam |
|
|---|---|---|
|
LS5 Treatment approach for stable glycemic control in patients with type 2 diabetes | |
| Luncheon symposium 6Sponsored by Takeda |
12:20~13:30 / Saturday 12 October Convention hall B Chairman:Seong Yeon Kim |
|
|---|---|---|
|
LS6 From evidence to value - reappraisal of combination therapy focusing on TZD/DPP4I | |
| Luncheon symposium 7Sponsored by Yuhan |
12:20~13:30 / Saturday 12 October Convention hall C Chairman:Yong Seong Kim |
|
|---|---|---|
|
LS7 A game changer for T2DM patients | |
-
Korean Diabetes Association
101-2104, Lotte Castle President, 109
Mapo-gu, Seoul, 04146, KoreaE-mail : icdm@diabetes.or.kr
-
Congress Secretariat (The Within)
5F, Samgyeong Bldg., #100-20, Yanghwa-ro, Mapo-gu, Seoul, Korea
TEL : 82-2-6959-5333 FAX : . 82-70-8677-6333 E-mail : icdm@diabetes.or.kr
